SOLID-STATE LASER SOURCE FOR CORNEAL ABLATION

准分子激光屈光性角膜切削术，一种用于矫正近视的新手术 目前，用ArF准分子激光去除角膜组织 在美国进行人体临床试验。准分子激光器是 相对复杂，在操作中使用可消耗的有毒气体。一个 固体替代准分子的成本将会更低- Chase和更低的维护成本。尽管FDA预计不会批准 直到1993-1994年，这种手术的巨大市场潜力已经导致 对基于替代技术的系统进行密集搜索。 由于没有高效的紫外光固体激光器，目标是 第二阶段计划将开发一种近红外信号源，该信号源可能是 通过四倍频移至207-220 nm区域。组织 将进行研究，以评估业绩差异 在这个波长区域和193 nm准分子之间。从长远来看 目标是开发一种固态紫外光系统，可以取代 现有屈光手术工作站中的准分子激光治疗仪。

Photorefractive keratectomy, a new procedure used to correct myopia by removing corneal tissue with an ArF excimer laser, is currently undergoing human clinical trials in the US. The excimer laser is relatively complex and employs expendable, toxic gases in operation. A solid-state alternative to the excimer would be less expensive to pur- chase and less costly to maintain. Although FDA approval is not expected until 1993-1994, the enormous market potential for this procedure has led to an intensive search for systems based on alternative technology. Since efficient UV solid-state lasers are not available, the objective of the Phase II program would be to develop a near-IR source that could be shifted to the 207-220 nm region via frequency quadrupling. Tissue studies would be performed in order to assess the performance differences between this wavelength region and the 193 nm excimer. The long term goal would be to develop a solid-state UV system that could replace the excimer in existing refractive surgery workstations.